AIMI Research Group Meeting: Prospective Evaluation of aBSI and PSMA-AI in a prospectively planned Phase 3 Studies in Prostate Cancer, Aseem Anand, PhD

Speaker(s): 
Aseem Anand, PhD
 

About:
Vice President, Digital Technologies EXINI Diagnostics AB, Sweden.

I believe that the future of digital healthcare belongs to the efforts that enable patients to control their healthcare data. Currently, I am at EXINI diagnostics AB, a subsidiary of Progenics Pharmaceuticals Inc., to provide patient-centric and data driven solutions for effective healthcare practice. Specifically, EXINI develops and validates machine learning algorithm as a medical device for diagnostic image analysis.

My passion is in using technology to solve clinically relevant problems. Before joining EXINI, I was a clinical researcher at Memorial Sloan Kettering Cancer Center, where I have worked to clinically validate biomarkers in prostate cancer - CTC, ctDNA and aBSI. I have received my PhD in nuclear medicine at Lund University, Sweden and Masters at Columbia University, New York